Detection and global quantification of cardiovascular molecular calcification by fluoro-18-fluoride positron emission tomography/computed tomography—A novel concept

Abstract

The aim of this study was to examine the degree and prevalence of regional (aorta) and global (cardiac) fluorine-18-sodium fluoride (${^{18}\text{F}}$-$\text{NaF}$) uptake by positron emission tomography (PET)–computed tomography (CT) as evidence for calcification in the atherosclerotic plaques in the aorta and the heart as a function of age. Image data from 51 patients, who had undergone whole-body $^{18}$F-NaFPET/CT, were evaluated retrospectively. Cardiac and arterial (aorta) radiotracer uptakes were analyzed quantitatively by measuring standard uptake values (SUV). This approach involved examining the entire heart and various aortic segments as identified by CT. By combining CT and PET data, regional and global concentrations of this molecule were calculated and correlated with age over the decades. $^{18}$F-NaF uptake in the heart and aorta increased significantly with advancing age ($P <0.01$). The Pearson correlation coefficient for the mean $^{18}$F-NaF uptake of cardiac regions and 5 age groups was 0.92 ($P=0.003$) and for aorta and 5 age groups was 0.97 ($P=0.004$). In conclusion, these preliminary data indicate the feasibility of $^{18}$F-NaF-PET/CT for measurement of regional and global calcification of the heart and major arteries. The $^{18}$F-NaF-PET/CT may provide highly relevant information about the state of calcified plaque before structural calcification is detectable by standard CT techniques. This, therefore, may allow for earlier intervention for risk reduction in cardiovascular diseases. Further studies are needed to validate the role of this promising technique in the management of patients with suspected atherosclerosis.

Introduction

Atherosclerosis and coronary heart disease (CHD) are the main causes of major morbidities and mortality in Western societies despite aggressive preventive strategies [1]. Atherosclerosis usually starts in the early decades of life and develops over the ensuing years, while often remaining asymptomatic until an acute life threatening event occurs during the course of the disease [2]. Furthermore, over half of acute myocardial infarctions or sudden cardiac death events occur in previously asymptomatic individuals [3]. Thus, there is a continued search for optimal biomarkers to allow for early and accurate identification of individuals at risk for this potentially fatal disease and subsequent implementation of timely interventions to modulate the atherosclerotic process.

Clinically, early detection of atherosclerosis should lead to initiating appropriate intervention before significant disease occurs, therefore, preventing serious complications in the future [4]. For this reason, the in vivo study of the atherosclerotic process, rather than its risk factors, will enable accurate and early identification of high risk individuals.

Although studies of coronary artery calcification (CAC) [5-7] and intimal medial thickness (IMT) [8, 9] have clinical utility for predicting future events, uncertainty [10, 11] among those without positive findings still exists [12]. These modalities do not accurately assess plaque characteristics [12, 13], including the composition and inflammatory state of plaques as well as the degree of molecular calcification which reflects plaque stability and, therefore, the risk of future clinical events [14-18]. Given the need for the development and validation of imaging techniques to allow for early detection and quantification of molecular changes in atherosclerotic plaque, we sought to assess whether imaging uptake of fluorine-18-sodium fluoride ($^{18}$F-$\text{NaF}$) would be successful in detecting the process of molecular calcification in the vasculature. If $^{18}$F-$\text{NaF}$ positron emission tomography (PET) imaging is successful in detecting cardiovascular calcifications, this may allow early intervention in the disease course and prior to overt calcification seen on computed tomography (CT). Since the degree of uptake of this radiotracer in the heart and major vessels is low, therefore visual detection of its presence and regional quantification of its concentration are suboptimal for the early assessment of this process. We introduce a new concept for calculating...
global calcification as a sensitive biomarker for detection of early molecular and cellular calcification in the atherosclerotic plaques. The results of this retrospective work based upon this novel premise form the basis for undertaking well planned prospective studies in the future. Thus, the purpose of this initial study was to assess the prevalence, location, and relationship of increased $^{18}$F-NaF uptake in the heart and aortic wall with normal aging as demonstrated by PET/CT as evidence for molecular calcification.

**Methods**

**Patients**
This study was approved by the local Institutional Review Board. In this retrospective study we examined the image data sets of 51 patients who had undergone $^{18}$F-NaF-PET/CT for evaluation of a variety of malignancies. The exclusion criteria included history of recent myocardial infarction, cardiomyopathy, pericarditis, myocarditis, recent radiotherapy to the thorax (within 3 months), amyloidosis, renal insufficiency, and active mediastinal bulky disease (e.g. lymphoma, granulomatous disease).

The mean age of patients was 63 years, ranging from 29-90 years. Seventeen (33%) were males, and 34 (66%) were females. Nineteen patients (37%) were ≤60 years old and 32 (63%) were >60 years old. Subjects were categorized into five age-groups: ≤40, 41-50, 51-60, 61-70 and >70 years old (Table 1).

<table>
<thead>
<tr>
<th>Age Group</th>
<th>Male</th>
<th>Female</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>≤40</td>
<td>1</td>
<td>1</td>
<td>2</td>
</tr>
<tr>
<td>41-50</td>
<td>2</td>
<td>5</td>
<td>7</td>
</tr>
<tr>
<td>51-60</td>
<td>3</td>
<td>7</td>
<td>10</td>
</tr>
<tr>
<td>61-70</td>
<td>5</td>
<td>15</td>
<td>20</td>
</tr>
<tr>
<td>&gt;70</td>
<td>5</td>
<td>6</td>
<td>11</td>
</tr>
</tbody>
</table>

**PET/CT imaging**
Imaging was performed on an integrated PET/CT system (Discovery LS®, GE Medical Systems, Milwaukee, WI) that consisted of a full-ring PET scanner with a 14.6cm transverse axial field of view and an in-plane spatial resolution of 4.8mm full width at half maximum at the center of the field and a four slice CT scanner. All PET scans were acquired in 2D mode (4min emission per bed position) and were reconstructed with standard reconstruction ordered-subset expectation maximization iterative algorithm (two iterative steps) and were reformatted into transverse, coronal, and sagittal planes.

The aortic valve was excluded from ROI to avoid contamination by the aortic wall or calcified aortic valve leaflets which might interfere with this analysis. Regions of interest were placed on all transverse images from the base to the apex of the heart with a fixed CT slice thickness of 4.5mm, and were then transferred to corresponding transverse PET images. Then, the volume of each slice was calculated by multiplying the area on the ROI by the slice thickness. Quantitative analysis of PET images was then performed by generating mean standardized uptake value (SUVmean) of each ROI.

**Image interpretation and quantitative data analysis**
Positron emission tomography scans were analyzed by an experienced nuclear medicine physician who was not aware of the clinical parameters or findings of the patients examined. Images were read and analyzed sequentially using an advanced PET/CT review software (Advantage Windows 4.2–7, GE Medical Systems, Milwaukee, WI), which allows simultaneous scrolling through the corresponding PET, CT, and fusion images in transverse, coronal, and sagittal planes.

![Figure 1](https://www.nuclmed.gr/)

Figure 1. This figure demonstrates a typical region of interest (ROI) that was assigned to the cardiac silhouette on each slices of CT and the corresponding PET slice. As noted above, the degree of $^{18}$F-NaF uptake is quite non-uniform throughout the selected slice and thus, is of limited value for accurate assessment of related calcification. Also, please note that the process of uptake is diffused and does not conform to the shape of the ventricles lumen in either ventricles. In this particular slice the volume of the selected ROI was 30.8 cc, and the SUVmean on the corresponding PET slice was 0.5. Therefore, the molecular calcification score for this particular slice was calculated to be 15.4 (30.8x0.5 = 15.4). The Global Calcification Score for the entire heart was calculated by adding the individual slice values generated by this approach.

The cardiac Global Molecular Calcification Score (GMCS) for each patient was generated as follows: for each transverse slice, the ROI volume of the tissue examined was calculated by multiplying the area of the ROI by its slice thickness. Then, the ROI volumes determined by CT were multiplied by the SUVmean generated from the same ROI assigned to
calculate the molecular calcification score in that particular slice. Finally, the cardiac GMCS was generated by summing the molecular calcification scores among the entire set of ROI analyzed.

For analysis of the aorta, fixed cylindrical volumes of interest (VOI) (with dimensions 20x20x30mm) were placed using transverse, coronal, and sagittal CT images for anatomic guidance. One VOI was placed over the lower thoracic aorta between the T4-T8 vertebral levels, and another VOI was placed over the abdominal aorta between the T12-L4 vertebral levels depending on the anatomic configuration of the aorta among different patients. Volumes of interest were then transferred to corresponding PET images. The SUVmean of the two VOI was recorded and averaged to generate aortic SUVmean as a measure of aortic molecular calcification.

Statistical analysis
Analysis was performed using the Stata 11 (StataCorp, 2009. Stata Statistical Software: Release 11. College Station, TX: StataCorp LP). An unpaired t-test was performed to assess for statistically significant differences in mean cardiac GMCS and aortic SUVmean for patients <60 vs. >60 years of age. Subjects were also categorized in predefined age groups (≤40 year, 41-50, 51-60, 61-70, >70) where results for each age group from PET/CT analysis were reported as mean (+standard deviation (SD)). Correlational analyses between mean cardiac GMCS and age group and between the mean of aortic SUVmean and age group were then performed to calculate Pearson correlation coefficients. We also evaluated whether renal function affects the GMCS to ensure that renal function changes would not influence the findings. To examine the effect of creatinine level on GMCS we categorized our subjects into four groups (by age (≤60, >60) and creatinine level (≤+predicted creatinine level (Hi), >predicted creatinine level (Low)).

By fitting regression models on the creatinine and age, we calculated predicted creatinine level of each subject based on their age. And then classified that subject into two categories of “Hi creatinine level”, if the measured creatinine level was higher than predicted value and of “Low creatinine level”, if the measured creatinine level was lower than predicted value. A t-test was performed to determine if there were differences between these groups with respect to GMCS.

P-values <0.05 were considered as statistically significant for all statistical analyses performed.

Results

Cardiac GMCS
The mean (±SD) of cardiac GMCS of each age group is presented in Table 2. The Pearson correlation coefficient for correlation between mean cardiac GMCS and the 5 age groups was 0.92 (P=0.003) (Fig. 2). The mean (±SD) of cardiac GMCS in patients ≤60 years of age was 25.6±2 whereas that in patients >60 years was 34.5±3 (P=0.04).

In younger subjects (age ≤60), the GMCS of “Hi creatinine” and “Low creatinine” groups were 38.63±9.37 and 28.86±5.84 respectively. And this difference was not statistically significant (P-value=0.43). Also in older subjects (Age >60) the GMCS of “Hi creatinine” and “Low creatinine” groups were 38.63±9.37 and 28.86±5.84 respectively. And this difference was not statistically significant (P-value=0.43). Also in older subjects (Age >60) the GMCS of “Hi creatinine” and “Low creatinine” groups were 38.63±9.37 and 28.86±5.84 respectively. And this difference was not statistically significant (P-value=0.43). Also in older subjects (Age >60) the GMCS of “Hi creatinine” and “Low creatinine” groups were 38.63±9.37 and 28.86±5.84 respectively. And this difference was not statistically significant (P-value=0.43). Also in older subjects (Age >60) the GMCS of “Hi creatinine” and “Low creatinine” groups were 38.63±9.37 and 28.86±5.84 respectively. And this difference was not statistically significant (P-value=0.43). Also in older subjects (Age >60) the GMCS of “Hi creatinine” and “Low creatinine” groups were 38.63±9.37 and 28.86±5.84 respectively. And this difference was not statistically significant (P-value=0.43).

Aortic molecular calcification
The mean ±SD of aortic SUVmean of each age group is presented in Table 3. The Pearson correlation coefficient for correlation between the mean of aortic SUVmean and the 5 age groups was 0.97 (P=0.004) (Fig. 3). The mean (±SD) of aortic SUVmean in patients ≤60 years was 0.83±0.04 whereas that in patients >60 years was 0.99±0.03 (P=0.004). The Pearson correlation coefficient between mean cardiac GMCS and aortic SUVmean measurements in each subject was 0.57 (P<0.01).

Table 2. Cardiac Global Molecular Calcification Score

<table>
<thead>
<tr>
<th>Age Group</th>
<th>GMCS: mean(±SD)</th>
</tr>
</thead>
<tbody>
<tr>
<td>≤40</td>
<td>21.00 ± 4.20</td>
</tr>
<tr>
<td>41-50</td>
<td>25.71 ± 2.98</td>
</tr>
<tr>
<td>51-60</td>
<td>26.46 ± 3.19</td>
</tr>
<tr>
<td>61-70</td>
<td>29.76 ± 2.71</td>
</tr>
<tr>
<td>&gt;70</td>
<td>36.65 ± 4.00</td>
</tr>
</tbody>
</table>

Table 3. Aortic SUVmean on 18F-NaF PET/CT

<table>
<thead>
<tr>
<th>Age Group</th>
<th>SUVmean: mean(±SD)</th>
</tr>
</thead>
<tbody>
<tr>
<td>≤40</td>
<td>0.72 ± 0.12</td>
</tr>
<tr>
<td>41-50</td>
<td>0.81 ± 0.06</td>
</tr>
<tr>
<td>51-60</td>
<td>0.86 ± 0.07</td>
</tr>
<tr>
<td>61-70</td>
<td>0.94 ± 0.03</td>
</tr>
<tr>
<td>&gt;70</td>
<td>1.10 ± 0.06</td>
</tr>
</tbody>
</table>
The results from this initial study demonstrate the potential feasibility of using $^{18}$F-NaF-PET/CT, and age. The aortic SUVmean data points (mean and SD) reflect $^{18}$F-NaF uptake in 5 different age groups as shown above. The fitted line shows a statistically significant increase in aortic molecular calcification with age (Pearson correlation coefficient $r=0.97$; $p=0.004$).

In general, minimal if any calcification was noted in the cardiac region on CT images. Some patients were noted to have calcifications in the aorta. Please note that we did not quantify the extent and degree of calcification on CT during this study. Of note, CT scanning was performed for attenuation and localization (of the PET findings) purposes. Conventional calcium scoring on CT requires high resolution gated imaging which was not available for these subjects. On $^{18}$F-NaF-PET images, no discrete or localized foci of radiotracer uptake were noted either in the cardiac region or aorta. As noted above, on the visual inspection, radiotracer uptake in the heart was diffuse but minimally perceptible.

**Discussion**

The results from this initial study demonstrate the potential feasibility of using $^{18}$F-NaF-PET/CT for in vivo quantification of molecular calcification in the heart and aorta, as an early feature of atherosclerosis in the evolution of its course. The finding that the degree of both cardiac and aortic calcification correlates significantly with age validates the theoretical notion that age is associated with the degree and extent of calcification. Therefore, this modality is potentially applicable to the management of patients with suspected atherosclerosis. Although preliminary in nature, our data show the first proof of concept for this technique and reveal that age, the most potent cardiovascular risk factor, is highly correlated with the degree of molecular calcification in the heart and aorta. These early results also provide approximate normal values and standard deviation for the GMCS which can be useful for future studies, particularly in patients at high risk for developing atherosclerosis.

The introduction of PET as a powerful clinical and research tool has rejuvenated interest for its utilization with $^{18}$F-NaF for assessment of osseous structures as well as early detection of calcification in the soft tissue [20, 21]. In particular, the significant shortage of technetium-99m ($^{99m}$Tc) for labeling a variety of compounds, and the greater availability, superior spatial and contrast resolutions, and potential for accurate quantification of PET and PET/CT compared with SPET and planar scintigraphy, prompted us to undertake this investigation. A large number of papers have been published in the literature that describe the utility of $^{18}$F-NaF-PET or PET/CT to assess malignant [22-25] and benign disorders of the skeletal system [26-28]. However, due to minimal uptake of either $^{99m}$Tc labeled compounds or $^{18}$F in the heart and the aorta as an evidence for molecular calcification has resulted in overlooking this very important phenomenon on planar scintigraphy and single photon emission tomography (SPET). Therefore, no attempt has been made to pursue the significance of this observation in both normal and pathologic states. This is particularly true when regional measurements, typically via placement of a single 2D ROI, are performed, which in this scenario tend to provide statistically insignificant data due to low signal to noise ratios. In contrast, the statistical reliability of this type of analysis can substantially improve by utilizing a global approach for disease evaluation as has been shown in other domains [29, 30].

The major reason for this initiating research study was to determine whether global measures of $^{18}$F-NaF uptake in the heart and aorta could be of value in detecting and quantifying molecular calcification in these structures and to assess the cause of atherosclerotic process. Our work extends the work of Derlin et al (2010) [31], who reported the feasibility of $^{18}$F-NaF-PET to image calcium deposition in the arterial wall as visualized by CT. The results from our study indicate that even without visible calcification in the heart and aorta, there is evidence for ongoing molecular calcification, which opens up a new avenue of research in atherosclerosis and effective management of this disorder. Global quantitative assessment of molecular calcification in the heart and aorta provides a novel and practical method of studying the course of atherosclerosis, to risk stratify patients with regard to clinical outcome early in the disease course, and to objectively monitor the effects of therapeutic interventions at various stages of this serious disorder.

Arterial calcification has been studied mainly through electron beam computed tomography (EBCT) [32] and multi-detector row computed tomography (MDCT) technologies, which are structural imaging techniques that are likely to provide limited functional or molecular characterization of atherosclerotic plaque [11]. These modalities detect structural macroscopic calcification, thereby providing information about atherosclerotic damage which has already occurred over the ensuing years [33, 34]. Also, there is presently a gap and controversy in the understanding of how CT imaging characteristics of atherosclerosis precisely relate to the natural history of atherosclerotic plaque [35-38, 16]. Furthermore, conventional CT imaging for this purpose is associated with significant radiation dose to the patient which is becoming a major source of concern in medicine.

Thus, the utilization of $^{18}$F-NaF-PET/CT imaging may be useful to bridge this gap, between cellular inflammation as detected by $^{18}$FDG-PET [39, 40] and CT calcification stage. It is conceivable that molecular calcification detected by $^{18}$F-NaF-PET/CT at earlier stages of the atherosclerotic process will allow for appropriate therapeutic intervention when the process is more likely to be reversible (Fig. 4). Local calcification has been implicated in plaque rupture [41], and the ability of $^{18}$F-NaF-PET/CT to provide information about both plaque function and structure in a single examination allows for its potential use in the risk stratification and treatment of...
patients with atherosclerosis. This is possible since the $^{18}$F ion exchanges with the hydroxyl group at the sites of molecular calcification, and a high degree of correlation been reported between the presence of calcification and the uptake of $^{18}$F-NaF on PET images [21]. It can be foreseen, that $^{18}$F-NaF-PET/CT can potentially provide information about different atherosclerotic phenotypes and associated probabilities of future cardiovascular events, which can then be modulated in the short- and long-terms with therapeutic interventions [42, 43, 14, 44].

In conclusion, our data provide evidence for feasibility of $^{18}$F-NaF-PET/CT for quantification of global molecular calcification of the heart and aorta, and by demonstrating statistically significant correlation between the uptake of the uptake in the heart and aorta with increasing age. Fluorine-$^{18}$F-NaF-PET/CT may therefore provide highly relevant information about the properties of calcified plaque long before macroscopic calcification will be detectable by CT, potentially allowing for earlier risk stratification and therapeutic intervention in a timely manner in patients with asymptomatic atherosclerosis.

The authors declare that they have no conflicts of interest.

**Bibliography**


17. van der Wal AC, Becker AE, van der Loos CM, Das PK. Site of intimal rupture or erosion of thrombosed coronary atherosclerotic plaques is characterized by an inflammatory process irrespective of the dominant plaque morphology. Circulation 1994; 89(1): 36-44.


